In my view you are making a legitimate point here that I have often wondered about.
But really we have no way of knowing what characterization methods Teva have used, let alone whether those methods may infringe MNTA's patents (assuming the patents hold up). And even assuming Teva are infringing, it's not clear to me how MNTA would know they are infringing.
But these patents may certainly be another potential hurdle for Teva - we just have no way of knowing.
Market Data 
Markets 
AI
